Banks Benefit From ...
Health Care: Drugs
Repligen Corporation (RGEN: NASDAQ)
$4.22 0.02 | 0.48%
02/09/12 - 04:00 PM ET
14.73K / 31.50K
Vol / Avg. Vol:4.21 / 4.20
Open / Prev. Close:4.18 - 4.25
Today's Range:2.90 - 5.31
52 Wk Range:22.19%
Performance YTD:TheStreet Rating:
Portfolios with RGEN
- Portfolio NameUser Type
- UserJan Jan Portfolio 1
- UserSUPRATRADE HOT STOCKS (BUY ...
- Userthedarbys Portfolio 1
- ProWinslow Green Growth - WGGFX
- Userlisakurt
- UserBVF Inc.
- Useredandboss Portfolio 1
- Userrandyhi Portfolio 1
- UserStock Screener 10 Tracking
- UserADF
Latest RGEN Headlines from TheStreet
- Biotech Calendar: Key Dates for August 08.02.11 | 10:08 am
- Eastman Kodak, Preferred Bank: Early Volume Plays 01.28.10 | 09:01 am
- Repligen Says Imaging Agent Misses Main Study Goal 12.09.09 | 10:12 am
- Health Winners & Losers: Abiomed 06.18.08 | 01:06 pm
- Tuesday's Winners & Losers: Garmin 04.08.08 | 04:04 pm
- Tuesday's Health Winners & Losers 04.08.08 | 04:04 pm
- Feuerstein's Biotech-Stock Mailbag 11.03.07 | 11:11 am
- ImClone Swings to a Loss 10.25.07 | 11:10 am
- Monday's Health Winners & Losers 09.10.07 | 04:09 pm
- ImClone Settles Patent Dispute for $65 Million 09.10.07 | 01:09 pm
Press Releases for RGEN
- Repligen Announces Conference Call Of Preliminary Third Quarter Fiscal Year 2012 Results - Business Wire 02.09.12 | 10:02 am
- Repligen To Present At BIO CEO & Investor Conference - Business Wire 02.07.12 | 07:02 am
- Repligen Announces Submission Of New Drug Application For SecreFlo™ For Improved Pancreatic Imaging In Patients With Pancreatitis - Business Wire 12.21.11 | 07:12 am
- Repligen Completes Acquisition Of Novozymes Biopharma Sweden AB - Business Wire 12.20.11 | 08:12 am
- Repligen Acquires Business Of Novozymes Biopharma Sweden AB - Business Wire 10.27.11 | 05:10 pm
- Repligen Reports Second Quarter Fiscal Year 2012 Financial Results - Business Wire 10.27.11 | 05:10 pm
- Repligen Announces Conference Call Of Second Quarter Fiscal Year 2012 Results - Business Wire 10.26.11 | 08:10 am
- Repligen Provides Q2 FY2012 Corporate Update - Business Wire 10.04.11 | 10:10 am
- Repligen To Present At Upcoming Investor Conferences - Business Wire 08.31.11 | 07:08 am
- Ronald L. Chez, A Private Investor, Files An Amended 13D For Repligen - PR Newswire 08.15.11 | 02:08 pm
Partner Headlines for RGEN
- 6 Cash Rich Biotech Stocks With Catalysts - Seeking Alpha 04.08.11 | 08:04 am
- Company News for March 08, 2011 - Corporate Summary - Zacks 03.08.11 | 10:03 am
- HEADLINE STOCKS-U.S. small/midcap stocks on the move on May 27 - Reuters 05.27.10 | 10:05 am
- UPDATE 1-FDA, EMA to re-analyze Repligen's late-stage data - Reuters 05.27.10 | 06:05 am
